Abstract
Overview
Introduction
In 2008, the six tumor types covered in this report are forecast to account
for over 1.2m new cases of cancer. Collectively, the 36 different drugs in
Phase III development for the six tumor types are forecast to achieve $7,049m
in sales by 2017. This constitutes a significant proportion of the oncology
market, thus representing ample commercial opportunities for drug developers.
Scope
- Examination of the solid cancer pipeline with in-depth clinical and
commercial profiles of Phase III candidates for six tumor types
- Seven major pharmaceutical market sales forecasts for Phase III pipeline
products through to 2017 with product-specific assumptions
- Segmentation and analysis of the current solid tumor pipeline by
developmental phase, drug class and indication for six tumor types
- Insight and analysis of market potential including commercial opportunity,
epidemiology, commonalities across cancers and discussion of unmet needs
Highlights
Avastin (bevacizumab; Genentech/Roche) has shown the greatest potential in the
ovarian cancer pipeline to date, with encouraging response rates in heavily
pretreated patients, alongside the commercially favorable backing of Genentech
and Roche, who have considerable experience in the oncology market.
Abiraterone (CB-7630; Cougar Biotechnology/BTG) shows the greatest potential
in the prostate cancer pipeline. Abiraterone shows real promise in providing
an effective therapy in the second-line or higher setting among patients where
all lines of antihormonal therapy and Taxotere (docetaxel; Sanofi-Aventis)
have failed.
In the RCC pipeline, Afinitor (everolimus; Novartis) shows the most promise,
by providing a treatment option for tyrosine kinase inhibitor-refractory
patients, who currently face a lack of viable therapies. Afinitor is the first
drug to show a Phase III clinical benefit in this patient population, which
could have a great impact on treatment.
Reasons to Purchase
- Identify key drugs and companies within the oncology pipeline based on
sales forecasts to 2017 and Datamonitor drug assessment
- Characterize unmet need and poorly served markets within oncology and
assess the potential for pipeline products to provide satisfaction
- Assess the shifting oncology market dynamic and how future treatment of
solid tumors will incorporate pipeline products
| 
View Cart
